• Sangamo Therapeutics selected winning bids in a court-supervised Chapter 11 asset auction totaling USD 163.55 million cash at closing.
• PTC Therapeutics set to buy the Fabry disease program ST-920 for USD 111 million, with up to USD 100 million tied to FDA approvals.
• Eli Lilly to acquire capsid delivery, zinc finger, MINT platforms, and prion program ST-506 for USD 50 million in cash.
• Separate sales of tools and equipment expected to add USD 2.55 million in cash proceeds at closing.
• Transactions await U.S. Bankruptcy Court sign-off; Lilly closing targeted around Sept. 4, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.